BP100 [Y10T]

General Information


DRACP ID  DRACP00705

Peptide Name   BP100 [Y10T]

Sequence  KKLFKKILKTL

Sequence Length  11

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=36.9±4.0µM MTT assay 48h 1
MCF-7/ADM Invasive breast carcinoma of no special type Carcinoma IC50=33.7±3.9µM MTT assay 48h 1
K562 Blast phase chronic myelogenous leukemia, BCR-ABL21 positive; Chronic myeloid leukemia Leukemia IC50=32.2±2.2µM MTT assay 48h 1
K562/ADM Blast phase chronic myelogenous leukemia, BCR-ABL22 positive; Chronic myeloid leukemia Leukemia IC50=39.5±3.7µM MTT assay 48h 1

Hemolytic Activity  Rabbit erythrocytes: 5% Hemolysis=160µM

Normal (non-cancerous) Cytotoxicity  GES-1: IC50=82.8±9.2µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00705

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C67H122N16O13

Absent amino acids  ACDEGHMNPQRSVWY

Common amino acids  K

Mass  153836

Pl  11.4

Basic residues  5

Acidic residues  0

Hydrophobic residues  5

Net charge  5

Boman Index  -766

Hydrophobicity  -13.64

Aliphatic Index  141.82

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 28474125

Title  Design, synthesis and biological evaluation of novel peptides as potential agents with anti-tumor and multidrug resistance-reversing activities

Doi 10.1007/s00726-017-2434-1

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.